WEHI-539 is a selective small-molecule inhibitor of the BCL-XL protein, designed as a research tool to investigate apoptosis and the intrinsic cell death pathway. As a potent BH3-mimetic, it specifically… Read more
WEHI-539 is a selective small-molecule inhibitor of the BCL-XL protein, designed as a research tool to investigate apoptosis and the intrinsic cell death pathway. As a potent BH3-mimetic, it specifically binds to the BH3-binding groove of BCL-XL to prevent its anti-apoptotic function, making it valuable for dissecting the survival mechanisms of various cancer cells in laboratory settings. This category provides access to high-quality reference standards, metabolites, and stable isotope-labelled compounds required to support precise analytical testing, impurity profiling, and method validation in pharmaceutical research. These materials ensure that researchers and laboratories can maintain rigorous quality control standards while exploring the therapeutic potential of targeting BCL-2 family proteins. Laboratories rely on these reliable reference materials to standardize assays and enhance the reproducibility of data during the evaluation of novel apoptotic agents.